Group 1 - The company Aisen Co., Ltd. (SH 688720) announced that its third board meeting for the year 2025 was held on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - As of the report date, Aisen Co., Ltd. has a market capitalization of 4.3 billion yuan [2] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a robust performance in the biopharmaceutical secondary market [2] - Despite the strong performance in the secondary market, the primary market for fundraising in the biopharmaceutical sector is experiencing a cooling trend [2]

截至发稿，奥比中光市值为344亿元。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 王可然） 每经AI快讯，奥比中光（SH 688322，收盘价：85.83元）10月24日晚间发布公告称，公司第二届第二十 次董事会会议于2025年10月24日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于2022年 限制性股票激励计划预留授予第二个归属期归属条件成就的议案》等文件。 2024年1至12月份，奥比中光的营业收入构成为：AIoT占比52.82%，生物识别占比40.93%，工业三维测 量占比4.69%，其他占比0.92%，其他业务占比0.64%。 ...

截至发稿，科蓝软件市值为83亿元。 （记者 曾健辉） 每经AI快讯，科蓝软件（SZ 300663，收盘价：17.32元）10月24日晚间发布公告称，公司第四届第一次 董事会会议于2025年10月24日以通讯表决的方式召开。会议审议了《关于选举公司第四届董事会专门委 员会委员的议案》等文件。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ 2025年1至6月份，科蓝软件的营业收入构成为：软件和信息产业占比100.0%。 ...

Group 1 - The core point of the article is that Cheng Tian Wei Ye (SZ 300689) held its sixth board meeting on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - Cheng Tian Wei Ye's revenue composition for the year 2024 is entirely from the smart card manufacturing industry, accounting for 100.0% [1] - As of the report date, Cheng Tian Wei Ye has a market capitalization of 5.9 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]

截至发稿，坤彩科技市值为121亿元。 2024年1至12月份，坤彩科技的营业收入构成为：珠光材料销售占比90.5%，二氧化钛占比7.86%，其他 占比0.84%，氧化铁占比0.71%，其他业务占比0.1%。 （记者 王晓波） 每经AI快讯，坤彩科技（SH 603826，收盘价：18.44元）10月24日晚间发布公告称，公司第四届第十七 次董事会会议于2025年10月24日在全资子公司正太新材料科技有限责任公司办公楼三楼会议室以现场结 合通讯表决方式召开。会议审议了《关于计提资产减值准备及核销资产的议案》等文件。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ ...

Group 1 - The core point of the article is that Wealth Trend (SH 688318) announced that Mr. Huang Shan has not reduced his shareholding in the company as of October 24, 2025, and the share reduction plan has expired [1] - For the year 2024, the revenue composition of Wealth Trend is 99.95% from computer services and software, with other businesses contributing only 0.05% [1] - As of the report, the market capitalization of Wealth Trend is 37.8 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market in biomedicine [1] - A conversation with Lu Gang, a partner at Chuangdong Investment, reveals that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]

Group 1 - Jin Fang Energy reported a revenue of approximately 691 million yuan for the first three quarters of 2025, representing a year-on-year increase of 9.69% [1] - The net profit attributable to shareholders of the listed company was approximately 89.8 million yuan, reflecting a year-on-year increase of 42.65% [1] - Basic earnings per share reached 0.57 yuan, which is a year-on-year increase of 42.5% [1] Group 2 - As of the report, Jin Fang Energy has a market capitalization of 2.8 billion yuan [2]

截至发稿，联赢激光市值为88亿元。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 曾健辉） 每经AI快讯，联赢激光（SH 688518，收盘价：25.64元）10月24日晚间发布公告称，公司第五届第十次 董事会会议于2025年10月24日以现场及通讯表决结合的方式召开。会议审议了《关于提请召开公司2025 年第一次临时股东大会的议案》等文件。 2024年1至12月份，联赢激光的营业收入构成为：动力电池占比71.53%，消费电子占比17.5%，汽车及 五金占比6.17%，其他业务占比2.42%，其他行业占比2.22%。 ...

Company Summary - Zanyu Technology (SZ 002637) announced on October 24 that shareholder Fang Yinjun has pledged 7.1 million shares to Bank of China International Securities, representing 29.83% of his total holdings [1][1][1] - As of the announcement date, Zanyu Technology has a market capitalization of 5.2 billion yuan [1][1][1] Industry Summary - For the first half of 2025, Zanyu Technology's revenue composition is as follows: 52.21% from the oil and fat chemical industry, 45.59% from daily chemicals, 1.75% from trade and other businesses, and 0.45% from processing services [1][1][1]

Group 1 - Company Aisen Co., Ltd. reported a revenue of approximately 439 million yuan for the first three quarters of 2025, representing a year-on-year increase of 40.71% [1] - The net profit attributable to shareholders of the listed company was approximately 34.48 million yuan, reflecting a year-on-year increase of 44.67% [1] - Basic earnings per share were 0.39 yuan, which is a year-on-year increase of 44.44% [1] Group 2 - As of the report, Aisen Co., Ltd. has a market capitalization of 4.3 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion US dollars this year [2] - The secondary market for biopharmaceuticals is thriving, while the primary market is experiencing a cooling in fundraising [2]